What is the Share Price of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd share price is ₹6,482.15 As on 19 December, 2024|00:40

Home
>
Stocks
>
Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd Share Price

Q: What is the Market Cap of Astrazeneca Pharma India Ltd?

The Market Cap of Astrazeneca Pharma India Ltd is ₹16,932 As on 19 December, 2024|00:40

Q: What is PE Ratio of Astrazeneca Pharma India Ltd?

The P/E ratio of Astrazeneca Pharma India Ltd is 132 As on 19 December, 2024|00:40

Q: What is PB Ratio of Astrazeneca Pharma India Ltd?

The PB ratio of Astrazeneca Pharma India Ltd is 23.83 As on 19 December, 2024|00:40

₹ 6,482.15 -46.95 (-0.72%)
Updated on 18-12-2024 4:38 PM

Stock Rating

Pros 3

Cons 4

Astrazeneca Pharma India Ltd Price Performance

Day's Low
₹6,442.55

Day's High
₹6,643.90

₹ 6,482.15

52-w low
₹4,600.70

52-w high
₹8,139

6,482.15

Day's open
₹6,548
Previous close
₹6,529.10
VWAP
₹6,536.15
Lower price band
₹5,223.30
Upper price band
₹7,834.90

Today's Market Action

The last traded share price of Astrazeneca Pharma India Ltd was 6,482.15 down by -0.72% on the NSE. Its last traded stock price on BSE was 6,463 down by -1.06%. The total volume of shares on NSE and BSE combined was 6,334 shares. Its total combined turnover was Rs 4.14 crores.

Astrazeneca Pharma India Ltd Medium and Long Term Market Action

Astrazeneca Pharma India Ltd hit a 52-week high of 8,139 on 07-10-2024 and a 52-week low of 4,600.70 on 20-12-2023. The stock price of Astrazeneca Pharma India Ltd is up by 2% over the last one month. It is up by 39.43% over the last one year. Don't forget to check the full stock price history in the table below.

Astrazeneca Pharma India Ltd Fundamentals

Market Cap (Cr): 16932
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Astrazeneca Pharma India Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Astrazeneca Pharma India Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Astrazeneca Pharma India Ltd

Data not available.

Astrazeneca Pharma India Ltd FAQ's

What is Share Price of Astrazeneca Pharma India Ltd?

What is the Market Cap of Astrazeneca Pharma India Ltd?

What is PE Ratio of Astrazeneca Pharma India Ltd?

What is PB Ratio of Astrazeneca Pharma India Ltd?

What is the CAGR of Astrazeneca Pharma India Ltd?

How to Buy Astrazeneca Pharma India Ltd Share?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 17.35. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.03. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only 11.86% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 94.44 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 164 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(19/12/2024)

100

Margin of Safety Index: High

100.00%

100.00% People are bullish about Astrazeneca Pharma India Ltd

0.00%

0.00 % People are bearish about Astrazeneca Pharma India Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %